Fig. 1

Changes from baseline in the ASAS treatment response domains through 52 weeks of treatment. LSM (weeks 1–16) and mean (weeks 20–52) changes from baseline in the ASAS treatments response domains (PtGA, spinal pain, function, and stiffness) for bDMARD-naïve (COAST-V) and TNFi-experienced (COAST-W) patients. The 16-week data have been published previously (10). At week 16, patients who originally received ADA or PBO were rerandomised 1:1 to ixekizumab Q2W or Q4W, while patients originally randomised to receive ixekizumab Q2W or Q4W continued treatment. ADA = adalimumab; ASAS = Assessment of Spondyloarthritis International Society; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; bDMARD = biologic disease-modifying antirheumatic drugs; IXE = ixekizumab; LSM = least squares mean; PBO = placebo; PtGA = patient global disease activity; Q = question; Q2W = every 2 weeks; Q4W = every 4 weeks; TNFi = tumor necrosis factor inhibitor